International Journal of Medical Science and Clinical Research
www.journalofmedical.com
Online-ISSN: 2664-7761, Print ISSN: 2664-7753
Received: 03-07-2022, Accepted: 20-07-2022, Published: 02-08-2022
Volume 4, Issue 2, 2022, Page No. 23-35

A review on Cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial Ischaemia-Reperfusion injury

Shreya Sunil Ahirrao, Anil Jadhav, Laxmikant Borse, Atul Bendale
Sandip Institue of Pharmaceutical Sciences, Nashik, Maharashtra, India

Abstract
During cardiac reperfusion after myocardial infarct The guts are vulnerable to cascading rounds of ischaemia reperfusion damage during cardiac reperfusion following a myocardial infarction (IRI) Myocardial dysfunction occurs in patients who have this injury, which leads to myocardial necrobiosis, which increases morbidity and death. New tailored treatments are needed to protect the myocardium from this damage and improve patient outcomes. The opening of the mitochondrial permeability transition pore has been identified as one of the most important sites contributing to this injury after extensive research into the role of mitochondria during ischaemia and reperfusion. This hole opens during reperfusion, producing mitochondrial expansion and dysfunction, as well as fostering apoptotic necrobiosis. Glycogen synthase kinase-3 suppression, uncoupling proteins, and mitochondrial ATP-sensitive potassium channels (mitoKATP) (GSK3). This review will summarise what has been discovered so far about statins and their cardioprotective effects on mitochondria during myocardial IRI.

Keywords: statins, mitochondria, MPTP, MitoKATP, Myocardialischemia-reperfusion injury

Introduction

Ischemic heart disease could be a major cause of morbidity and mortality in Western civilization. Despite the fact that interventions such as thrombolysis and coronary percutaneous interventions have been shown to be effective in ischemic stroke and recurrent injury, it is a fundamental pathologic process for ischemic heart disease, laboratory studies suggest that more protection is possible, and a large effort is being made to bring new therapeutic options to the clinic. Ischemia and reperfusion damage, as well as cardiomyopathy, are both caused by mitochondrial dysfunction. Despite the fact that promising mitochondria-targeted medications have emerged from the lab, only a few have made it through clinical trials. As a result, the mitochondrion could be a promising new target for ischemic heart disease and cardiomyopathy treatments.



Fig 1: Statins

Myocardial Ischaemia-reperfusion injury

Myocardial reperfusion injury is defined as the death of myocytes that were alive at the moment of reperfusion as a direct result of one or more reperfusion-induced events. Anti-inflammatory and antioxidant effects are found in statins (Figure 1) Perioperative statin medication has been shown in two randomised studies to minimise myocardial damage and enhance cardiac function [1, 2]. Perioperative rosuvastatin in Cardiac Surgery, a major randomised trial recently described by Zheng [3], found that perioperative rosuvastatin Many medications include antioxidant potential, which may contribute to their pharmacological action, according to medication. Tissue

injury is mediated by endothelial and leukocyte responses, which are regulated principally by the complement cascade. Anaphylatoxins and the construction of the membrane assault complex both lead to further tissue injury, both directly and indirectly. The depletion of complement components is frequently used to salvage tissue, indicating that the complement cascade plays a role in ischemia/reperfusion injury. The complement cascade's intricacy makes it possible to target several areas for therapeutic therapies aimed at modulating the complement response to injury. The power of a person exemplifies the latter. ischemia/reperfusion injury also as it prevents myocyte and vascular injury and organ dysfunction by preventing assembly of the membrane attack complex. Complement inhibitors are not limited to newly discovered chemicals or molten versions of complete activation controls. Concomitant activation is known to inhibit common therapeutic drugs such as heparin and related non-anticoagulant glycosaminoglycans. Both *in vitro* and *in vivo*, should be as beneficial as cytoprotective agents. Heart disease is the leading cause of death in the world. Ischemia / reperfusion (I / R) injury is among the most common aetiology cardiovascular diseases. Ischemic heart disease is the leading cause of death worldwide, according to the World Health Organization, responsible for about 9 million fatalities in 2016. Cardiovascular events are treated with thrombolysis, percutaneous trans luminal coronary angioplasty, or coronary bypass surgery. When coronary artery disease occurs, myocardial I/R damage might occur. This injury is caused by a variety of pathophysiological processes, including elevated reactive oxygen types. It will be a crucial factor. Cell kinds include platelets, fibroblasts, endothelium and smooth muscle cells, and immunological cells. Reperfusion-induced cardiac I/R injury is also linked to polymorphonuclear leukocytes. Many natural antioxidant systems have been proven to defend it, therefore this damage could be insufficient in individuals with co-morbidity. According to the findings, optimal cardioprotection may require a combination of supplementary or synergistic multi-target therapy.

Effects of acute myocardial ischaemia/reperfusion injury on the coronary vasculature

1. Endothelium, pericytes, and glycocalyx(Fig 2 Endothelium, pericytes, and glycocalyx)

Coronary endothelial cells are resistant to ischemia and can withstand hypoxia for several days *in vitro*. *In vivo*, however, antegrade pulsatile flow suspension and shear pressure cause endothelial cells to proliferate and bleb. The weakening of cellular connections may contribute to endothelial degeneration and subsequent cell proliferation after implantation. Increased cytosolic calcium activates endothelial contractile elements, and their uptake stimulates the formation of cohesive gaps, which increases the penetration of large molecules into the reconstituted endothelium. The production of adhesion molecules by activated endothelial cells and platelets leads to platelet-leukocyte binding and adhesion to the coronary microvasculature. In addition, cytokine release disrupts cell junction stability and promotes vascular flow. NLRP3 activation of inflammasome in endothelial cells may induce caspase 1-mediated necrobiosis by activating Src and separating VEGFR2 / vascular endothelial (VE) -cadherin complex. Inflammation initiated by Endothelium, which is associated with the effects of inflammation from cardio myocyte necrosis, results in the activation of inflammatory cells and the release of inflammatory substances such as vascular endothelial protein (VEGF), matrix metallo proteases, thrombopx, thrombopx, and platelet activating factor. These factors, too, increase vascular permeability and cause myocardial edema through a variety of mechanisms, including VEGF-induced NOS activation in caveolae. Angiopoietin-1 and angio poietin- like peptide 4 prevent endothelial cell interactions by strengthening them.



Fig 2 Endothelium, pericytes, and glycocalyx

Pericytes promote cerebral microvasculature vasoconstriction, trapping red and white blood cells in non-flowing areas within the post-ischemic brain. Although there are many pericytes in the coronary microvasculature, little is known about their role in the gut. The presence of pericyte and capillary width decreased was associated with capillary obstruction in the heart of repeated mice, suggesting that cardiac pericyte can clog the coronary capillaries and reduce micro vascular blood flow after acute myocardial infarction (AMI). Pericyte relaxing adenosine increases capillary diameter, reduces blockage, and increases discharge volume. Therefore, pericytes in the heart can be a new treatment to prevent coronary microvasculature.

2. Oedema

Intracellular fluid forms a large portion of the myocardial fluid, and cardiomyocyte inflammation occurs immediately after coronary flow. Osmotic inflammation causes sarcolemmal fractures and necrobiosis, and hyperosmotic reperfusion can reduce myocardial edema and MI size. In heavy cardiomyocytes, intracellular edema is reversed by restoring ion pump function, particularly the sarcolemmal Na + / K + -ATPase. Transmission with normo-osmotic blood causes rapid interstitial edema because the formation of metabolites increases interstitial osmolality during ischemia. Catabolite baths reduce the osmotic tendency between intravascular and interstitial compartments, causing interstitial edema to decrease, but increased vascular permeability causes a second wave of edema. After re-implantation, a serial cardiovascular resonance (CMR) study in pigs revealed a bimodal pattern of myocardial edema.

3. Platelets

Endothelial cells produce prostacyclins, NO, and adenosine, which inhibit platelet aggregation and adhesion. However, they release adhesion molecules and release the Willebrand factor, which, when activated, leads to platelets to form clogs. Activated platelets, on the other hand, release vasoconstrictive substances including ADP, serotonin, and thromboxane, which reduce the inhibitory activity of coronary microvessels within the heart. The heart of the mouse benefits from plasma-rich plasma concentrations. In the hearts of mice treated with IRI, platelet aggregation of rats or supernatant of platelet- mice activated. reducing myocardial damage as measured by cardiac enzymes and improved function. Some mechanism is uncertain, however S1P, adenosine, serotonin, or thromboxane A2 may be involved. Mixing of platelet extracts from the hearts of guinea pig after IRIcomponents The integrity of the coronary endothelium is maintained. *In vivo* research produces more important clinical information than *in vitro* studies, which are significantly lower and more natural. Pigs were given a platelet integrin IIb3 receptor antagonist lamifiban before implantation after 55 minutes of cardiac ischemia. Lamifiban although it stopped platelet aggregation and had a strong antithrombotic effect on the wound, it did not affect microvascular platelet aggregation or MI severity. In the vivo mouse model, the left arteria coronaria was detained for 30 minutes and then detained for 24 hours.

Microvascular obstruction as a target for cardioprotection

Micro vascular obstruction (MVO) is a clinically reversible event that is clinically seen as coronary recurrence within the infarct-related artery after the first PCI and is defined as "inability to reuse the previous ischemic area" during AMI. MVO aetiology has been linked to endothelial inflammation and blebbing, cardiomyocyte inflammation of the capillaries, platelet function and consolidation, capillary blockage due to red and white corpuscle blood stasis, and coronary micro embolization (updated on). Excessive MVO may cause capillary damage. Increased red blood cells in the myocardium, known as intramyocardial haemorrhage (IMH), is a condition that predicts adverse outcomes after AMI.MVO is usually associated with infarction after recurrent recurrent myocardial ischemia. MVOs and non-drainage areas are characterized by instability within the embedded tissues and not in the hazardous, active environment. There is also infarction other than MVO or no-reflow. These findings suggest that MVO is the result of myocardial infarction rather than the cause. For technical reasons, MI size is only available in a reliable way and is limited after a few hours of re-installation. As a result, any premature and temporary MVOs involved in infarct expansion may not have been reported. Impact on MI size and MVO in response to cardioprotective treatment frequently isolated ischemia ischemia remotely isolated in pigs that reduce MI size but not regions that can flow again. Delay of hypothermia during reconstruction, on the other hand, reduces the recurrence but not the magnitude of MI. MVO and cardiomyocyte mortality are caused by the same factors that cause cardiomyocyte death (necrosis, apoptosis), although their contributions to MVO and cardiomyocyte mortality may vary. The causality between MVO and cardiomyocyte necrobiosis is not yet known, so these two disorders should be seen as distinct but closely related, perhaps because of similar underlying mechanisms. Even after rapid epicardial resuscitation of the infarct-related artery, MVO and coronary and reflow occur frequently and have a significant impact on patient prognosis. Several MVO prevention strategies successfully tested on AMI test models have failed to explain clinical trials in AMI patients.

Intramyocardial haemorrhage as a target for cardioprotection



Fig 3: Microvascular CMR

IMH may occur after infarct arterial coronaria recurrence. After 50 to 60 minutes of closure and reintroduction into the hearts of dogs, IMH grows within the central infarct; Ultrastructurally, the endothelium is disrupted in many areas. After AMI lytic treatment, IMH was detected in humans during post-mortem examination. IMH is not specific to thrombolysis, however it is more common after mechanical duplication and has been linked to adverse clinical outcomes. The relationship between MI size and MVO and clinical side effects is very strong. IMH is linked to higher MI, longer duration of treatment, and, consequently, the use of glycoprotein IIb / IIIa inhibitors. With a continuous response to inflammation, the release of erythrocyte, leukocyte, and eventually iron deposits increases myocardial damage. AMI. Endothelial inhibition function of microspheres of 0.1 m diameter was lost in the hearts expressed in the first 30 min ischemia followed by 60 min repetition, and the inhibitory function remained stable after 30 min ischemia without repetition, with better preservation of junctions endothelial cells and small endothelial cells. cell damage in the ex vivo mouse model. A treatment window for binding microvascular disease appears to exist based on this sequence of events. (Figure 3 Microvascular CMR) damage and IMH followed by re-installation. The first series of CMR-scanning acutely after STEMI showed some changes within the infarct core up to 50% of patients treated with primary PCI Using LGE, many patients showed completely empty areas. Later, For IMH in particular, a non-differential sequence was introduced. The release of oxy haemoglobin, deoxyhaemoglobin, and methaemoglobin alters CMR tissue structures, as evidenced by the decrease associated with time constraints and consequently the corresponding signal reduction within the infarct zone. The addition of ferritin and hemosiderin ions also causes signal reduction, which is exacerbated by edema and as a result there is a significant decrease in blood loss, making it a more accurate sequence of IMH detection. The question of whether CMR-defined MVO and IMH are separate entities is still being debated. There was a significant collection between the LGE obtained by MVO and T2 identified by IMH in a combined patient and pig study. Severe bleeding and complete microvascular injury were present in these areas, which were limited to the infarct spine. The real MVO is only visible within the infarct border area.

Targeting the coronary vasculature for cardioprotection

Interventions to protect coronary vasculature following deep IRI progressively during AMI are aimed at endothelial dysfunction, endothelial integrity, micro embolization, vasomotor dysfunction, cardiomyocyte and endothelial compression - compression -capillaries, as well as capillary fractures and IMH institutional IMH in general. Separation between necrosis. endogenous cardioprotective techniques, collectively referred to as ‘ischemic conditioning’ and include the use of 1 or more short cycles of non-lethal ischemia and re-intervention in the center itself, before fatal ischemic stroke (IPC), or early recurrence (i Isischemic post conditioning (Posted) Such a cardioprotective stimulant can also be used on a remote organ or remote [remote ischemic conditioning (RIC)] or before [remote ischemic preconditioning (RIPC), or during a fatal ischemic episode. ischemia in cardiomyocytes and neglected coronary vasculature has been the focus of many diagnostic and therapeutic studies. the situation is clear cut coronary vasculature without cardiomyocytes.

Actions of statins in targeting mitochondrial dysfunction (Figure 4 Actions of statins in targeting mitochondrial dysfunction)

Statins that lower cholesterol effectively lower the risk of serious cardiovascular events. Myopathy is a potentially fatal side effect, although the cause is unknown. Several statin lactones impair respiratory capacity in C2C12 myoblasts and appear to be potent inhibitors of mitochondrial complex III (CIII) function, inhibiting it by

up to 84 percent. Lactones were 3 times more effective at inducing cytotoxicity than their acid counterparts. For statin lactones, the Qo binding site of CIII has been discovered to be accidental. These findings may be validated in the muscle tissue of patients with statin-induced myopathies, where the enzyme CIII activity is lowered by 18%. Inhibition of respiration in C2C12 myoblasts can lower the flow of flexible electron CIII and restore respiration to up to 89 percent of control. Finally,



Fig 4: Actions of statins in targeting mitochondrial dysfunction

Statins (HMG-CoA reductase inhibitors) are cholesterol-lowering drugs that are effective in reducing the danger of major cardiovascular events. They're among the foremost commonly prescription drugs worldwide. Although statins are generally well tolerated, myopathies are the foremost frequent adverse effects, starting from muscle pain with rates up to 26% to very rare cases of life-threatening rhabdomyolysis

The effect of statins on mPTP opening

Cardiomyocyte death due to short-term ischemia occurs mainly within the first few minutes after recurrence of contraction band necrosis with sarcolemmal rupture. During this form of necrobiosis, cardiomyocyte hypercontracture produced by restoring and restoring pH prior to poor cytosolic control of Ca2 +, as well as calpain-mediated cytoskeletal fragility, plays an important role. The gap junction allows hypercontracture to spread to neighboring cells. The opening of the mitochondrial fluid opening has recently been linked to reperfusion-indeed necrosis, although the direct relationship with hypercontracture has not been determined. Studies have shown that treatments used during recovery, including contractile blockers, Na + / Ca2 + exchange inhibitors, gap junction blockers, etc., can significantly reduce the size of the infarct. and the effects of current drugs with potential cardioprotective effects may be poorly established or poorly understood. Efforts should be made to address the unresolved issues by means of necrobiosis cell-based mechanisms caused by blood duplication, new diagnoses and tests, and the production of appropriate drugs. The potential benefits of reducing the size of the infarct in people receiving treatment for acute myocardial infarction are significant. Treatment of mitochondrial respiratory chain complexes in the hippocampus and striatum of mice with atorvastatin and MPTP. Atorvastatin (Ator, 10 mg / kg, p.o.) or saline (control) was given for seven consecutive days, the trial began six hours after the administration of MPTP.

Mitochondrial MPTP

The port of mammalian mitochondrial permeability transition pore (MPTP), across the inner and outer membranes of the mitochondria, can be an indirect channel for signal transmission or transfer of material between a mitochondrial matrix and a cytoplasm such as Ca2 +, an antidote control, protein. It is expressed in various motives. Continuous efficacy of MPTP has been shown to induce neuronal apoptosis in ischemic stroke. At the same time, MPTP inhibition caused by over-exposure showed efficacy during the treatment of ischemic stroke. Among them, the potential therapeutic mechanisms for stroke have been gradually revealed by researchers. Multi-component or multi-target drug features also offer the opportunity to treat a side effect from mitochondrial MPTP attitude. The benefits outlined above make it necessary for us to explore and clarify the new concept of international medicine in the treatment of stroke and to find precise molecular mechanisms where advanced technology is as large as possible. We plan to highlight the link between abnormal MPTP rupture and neuronal apoptosis in ischemic stroke. We also summarized the currently approved drugs, prescription drugs, remedies, and monomer compounds identified to prevent MPTP from being exposed to ischemic neuron apoptosis. Finally, we attempt to provide a dynamic perspective and enlightenment of

traditional medicine within the prevention and treatment of stroke by MPTP inhibition of neuronal apoptosis. A complex mitochondrial permeability transition pore (MPTP) may be an indirect and selected channel. It is made up of many proteins, which are dependent on voltage and include the cytoplasm, the outer mitochondrial membrane (OMM), the inner mitochondrial membrane (IMM), and the mitochondrial matrix. Excessive MPTP exposure has been reported to myocardial ischemia reperfusion hepatic reperfusion The port of mammalian mitochondrial permeability transition pore (MPTP), across the inner and outer membranes of the mitochondria, can be an indirect channel for signal transmission or transfer of material between a mitochondrial matrix and a cytoplasm such as Ca2 + homeostid, an antidote control , protein. It is expressed in various motives. Continuous efficacy of MPTP has been shown to induce neuronal apoptosis in ischemic stroke. At the same time, MPTP inhibition caused by over-exposure showed efficacy during the treatment of ischemic stroke. Among them, the potential therapeutic mechanisms for stroke have been gradually revealed by researchers. Multi-component or multi-target drug features also offer the opportunity to treat a side effect from mitochondrial MPTP attitude. The benefits outlined above make it necessary for us to explore and clarify the new concept of international medicine in the treatment of stroke and to find precise molecular mechanisms where advanced technology is as large as possible. We plan to highlight the link between abnormal MPTP rupture and neuronal apoptosis in ischemic stroke. We also summarized the currently approved drugs, prescription drugs, remedies, and monomer compounds identified to prevent MPTP from being exposed to ischemic neuron apoptosis. Finally, we attempt to provide a dynamic perspective and enlightenment of traditional medicine within the prevention and treatment of stroke by MPTP inhibition of neuronal apoptosis. A complex Mitochondrial permeability transition pore (MPTP) may be an indirect and selected channel. Is made up of many proteins, which are dependent on voltage and include the cytoplasm, the outer mitochondrial membrane (OMM), the inner mitochondrial membrane.

Causality between Abnormal MPTP Opening and Apoptosis in Ischemic Stroke

The abnormality of MPTP status is sure to cause cellular dysfunction in ischemic stroke. we will briefly summarize the features associated with MPTP cells aimed at initiating apoptosis after ischemic stroke. external number of previous reports have shown that stroke-induced MMP decreases, active mitochondrial oxygen levels (mtROS) (endoplasmic reticulum stress (ERS), and high levels of amino alkanoic acid all trigger the release of MPTP leading to edema - i -mucosa, paralyzed IMM cristae structure, with neuronal apoptosis Implementation of MPTP MPTP, can start MPTP in the pocket.Ligands targeted at VADC, ANT, CypD), and targeted TSPO / PBR show better prevention of MPTP exposure. In addition, antioxidants such as propofol, metabolites such as glucose and creatine, ubiquinone, glutamate, or Ca2 + chelators may inhibit MPTP activity.

It has been reported that the onset of ischemic stroke causes neurons to induce MtROS, ERS, Ca2 + overload, and neuronal toxins caused by excitatory amino acids. Then, neurons can initiate signaling reduction of MMP, mitochondrial edema, elevated MMP and other MPTP signaling pathways, which may eventually trigger mitochondrial content such as Cyto-c to be released into cytoplasm and causes apoptotic events. Effects of *in vivo* animals Studies have shown that both temporary and permanent cerebral ischemic shock can cause damage to the mitochondrial ultrastructure of the neuron, such as the emergence of swollen mitochondria and condensate, and matrix elevation caused by electron-dense suspension material Ischemia ,-Othosiwe ROS MPTP. Effectively, which may lead to subsequent ROS production and blood loss Therefore, inhibiting neuronal apoptosis by inhibiting MPTP activity may be an effective and promising strategy within ischemic therapy. Numerous *in vivo* and *in vitro* tests have also suggested a positive effect of this treatment. In mouse models of ischemic stroke, inhibition of MPTP release by cyclosporine A has been shown to reduce the infarcted volume of ischemic brain tissue Like a CypD-directed ligand, previous administration of cyclosporine A may protect mouse neurons from injury. of OGD / R, methods involved. It may also be associated with maintaining mitochondrial integrity and preventing MPTP induction by apoptosis by activating Parkinson's disease-related protein DJ-1 In addition, water-soluble coenzyme Q10 has been shown to monitor the formation of HT22 hippocampal neuron. is produced by glutamate. by preventing mitochondrial separation and MPTP for apoptosis). Additionally, evidence has shown that MPTP interventions to open inhibitors may reduce VDAC expression, indicating an increase in MMP, ATP supply, and symptoms of cerebral ischemia injury in the *in vitro* rat model of MCAO All the above evidence indicates the ischemic stroke of MPTP. opening may also be a factoid of neuronal apoptosis. Any measures to prevent MPTP activation can suppress cell apoptosis, thereby demonstrating the role of the ischemic immune system. MtROS, ERS, Ca2 + overload, and neuronal toxins caused by excitatory amino acids. then, neurons can initiate reduced MMP expression, mitochondrial edema, elevated MMP and other MPTP signaling pathways, which may initiate mitochondrial-like content such as cytoplasm and cause apoptotic. Animal experimental results *in vivo* have shown that both temporary or permanent cerebral ischemic shock can cause damage to the mitochondrial ultrastructure of the neuron, such as the emergence of swollen mitochondria and condensate, and the height of the matrix caused by an electron-dense dangling element. Ischemia. - Fried ROS can cause MPTP activation, which may lead to subsequent ROS production and blood loss Therefore, inhibition of neuronal apoptosis by inhibiting MPTP activity may be an effective and promising strategy within the treatment of ischemic stroke. Numerous *in vivo* and *in vitro* tests have also suggested a positive effect of this treatment. In mouse models of ischemic stroke, inhibition of MPTP release by cyclosporine A has been shown to reduce the infarcted volume of ischemic brain tissue Like a CypD-directed ligand, early administration of cyclosporine A may protect mouse neurons from injury. of OGD / R, methods involved. It may also be associated with maintaining mitochondrial integrity and preventing MPTP induction by apoptosis by activating

Parkinson's disease-related protein DJ-1 In addition, water-soluble coenzyme Q10 has been shown to monitor the formation of HT22 hippocampal neuron. is produced by glutamate. by preventing mitochondrial separation and MPTP for apoptosis). Additionally, evidence has shown that MPTP interventions to open inhibitors may reduce VDAC expression, indicating an increase in MMP, ATP supply, and symptoms of cerebral ischemia injury in the *in vitro* rat model of MCAO All the above evidence indicates the ischemic stroke of MPTP.

The action of statins on mitophagy

Statins trigger mitophagy linked to ubiquitin ligase Parkin and adapter protein p62 / SQSTM1. Additionally, a decrease in statin-mediated CoQ causes mitochondrial depletion, causes mitophagy, and reduces the production of active oxygen species. statins are a class of prescription drugs that block 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an enzyme that lowers cholesterol biosynthesis, and is used as an anti-hypercholesterolemia. Cholesterol reduction agents are believed to slow the progression of atherosclerosis. In addition to its obvious effect of lowering blood cholesterol levels, statins have additional beneficial effects, including reducing oxidative stress and inflammation, and stabilizing atherosclerotic plaque. of vivo, such as mice, dogs, and pigs. -ischemia or during the onset of recurrence of reperfusion (Interestingly, excessive use of statins before ischemic shock has been shown to provide cardio protection without altering serum cholesterol levels, highlighting the immune system for non-lipid-lowering cardio-lowering diseases, in part by reducing the activity of nicotinamide adenine dinucleotide phosphate oxidase Stat ins reportedly improves mitochondrial function even though it requires adverse effects on striated muscle 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in hospitalized patients due to acute Immediate myocardial infarctitis.This study reveals a completely different role of mitophagy in statin cardioprotection against ischemic damage.it causes mitochondrial degeneration, causes mitophagy, and reduces the production of active oxygen species. in farct with acute statin administration in mice eliminates CoQ interactions. The findings raise the question of whether CoQ supplements could interfere with the cardioprotective benefits of lemon statins by mitophagy. Our laboratory *et al*. demonstrated autophagy activity in cardioprotection against I / R injury [reviewed by Gottlieb and Mentzer [13]]. Autophagy may be a cell-storage function responsible for the destruction of large amounts of protein aggregates or damaged organelles. Recently, we reported that Parkin-based mitophagy is important for cardioprotection by ischemic preconditioning [18]. Several groups have shown that statins that promote autophagy, however, the link between statinoprotection cardioprotection and autophagy (and more interestingly, mitophagy) has not yet been established. Our previous findings have led us to develop a novel view that statins mediate cardio protection by regenerating mitophagy and reorganizing the existing mitochondrial heart system within the heart. During this study, we aimed to clarify the mechanisms that regulate statin-mediated cardiac protection, and to clarify the role of autophagy / mitophagy during this process.

Mitophagy in Cardiovascular Diseases

Fundamental Aspects of Mitophagy



Fig 5: Mitophagy



Fig 6: Atherosclerosis

Mitophagy was first identified in yeast, when two independent study groups examined mitophagy deficiency and identified a gene associated with autophagy 32 (Atg32), which is important in mitophagy. Previous studies have suggested that the genes Aup1p and Uth1p are involved in autophagic damage to mitochondria however, these factors were not identified during genomic testing. In mammals, the first detection of mitophagy was performed during the maturation of reticulocytes. Adult red blood cells do not have mitochondria because immature red blood cells lose mitochondria through mitophagy during isolation. The event also mediates the protein OMM BCL2 / Adenovirus E1B 19 KDa Protein-Interacting Protein 3-Like (BNIP3L; also known as NIP-3-Like Protein X, NIX), the expression of which grows during maturation. NIX contains the motif needed to assemble a microtubule associated with microtubule protein 1 (MAP1) light chain 3 (LC3 locally formed over the autophagosomal membrane and mediates the removal of mitochondria from autophagy vesicles. -Nix / BNIP3L shares 50% homology with BCL2 Interacting Protein 3 (BNIP3) interestingly, this factor is involved in autophagy and mitophagy under hypoxic conditions both in cancer and during myocardial ischemia / reperfusion (I / R) injury. (IRI) [These findings suggest that mitophagy in mammals may be a localized pathway. called Parkin, and PTEN-induced kinase. 1 (PINK1), its protein product is a local kinase. PINK1 enters the mitochondria through the activity of the outer tran membrane solaces (TOM) and reaches the inner mitochondrial membrane through the activity of the internal membrane translocate (TIM), which acquires signalling sequence of amino-terminal mitochondrial. During these implantation steps, PINK1 is subjected to a series of proteolytic cleavage events by intermembrane serine protease presently-associated rhomboid-like protein (PARL), and the full-length form 64 kDa is then divided into 60 kDa and 52 fragments. When KDa is released from cytosol, the 52-kDa component is then depleted of the proteasome Overall, these mechanisms allow for the maintenance of very low levels of PINK1 during stress. conditions. everywhere TIM / TOM scattered; PINK1 re-accumulates in OMM mitochondria only and is based on the complex structure of TOM7, TOM40, TOM70, TOM20 and TOM22 PINK1 mediates two different phosphorylation events aimed at modifying Auto inhibited E3-ubiquitin phosphorin Active enzyme - a. The first step involves auto

phosphorylation in S402, S228 and T257. Interestingly, genetic mutations in these fossils interfere with both PINK1 activation and paraxial detection in the mitochondrial region. Finally, PINK1 initiates the addition of a. phosphate in S65 for Ub. As a result of this complex uncontrolled action, the activation of E3 gas in Parkin is activated, allowing you to obtain mitochondrial proteins by direct contact with phospho-Ub conjugates in mitochondria. The presence of these poly-Ub chains promotes reactivation of Ub-binding autophagy receptors to link damaged mitochondria to LC3-positive phagosomes to bind to lysosomes. The actual study suggested that p62 / sequestosome 1 (p62 / SQSTM1) was the main receptor involved in the Posterior mitophagy study showed that in addition to p62, at least four other receptors, the Brca1 (NBR1) neighbor, nuclear fleck protein 52 (NDP52))), optineurin (OPTN) and TAX1BP1 (TBK1), are involved during the breakdown of damaged mitochondria. Despite a large number of studies, what is even more important for mitophagy remains unclear (Penta-knockout (KO) cell lines at all five receptors suggesting that Nuclear Sphere 10 Protein 52 (NDP52) and OPTN are only needed for successful mitophagy.However, this experiment was performed with a single cell line, and not all cell types and apki have the same characteristics of these characters.

Mitophagy in Cardiovascular Diseases

1. Atherosclerosis (Figure 6. Atherosclerosis)

Atherosclerosis (AS) is a habitual seditious complaint that's common in advanced countries. Because to shrine buildup inside the arterial lumen, the commerce of lipid accumulation, increased vascular smooth muscle cell (VSMC) proliferation, matrix development, calcification, and inflammation causes a considerable condensation of the highways. Colorful styles, similar as electron microscopy, luminescence microscopy, and western spot approaches, have been used to examine autophagy in cells that induce atherosclerotic pillars (VSMCs, endothelial cells, macrophages) over the last ten times. Grounded on the identification of the autophagic labels p62 and LC3-II in cells insulated from pillars, studies on mortal samples and mice models of AS have indicated either conking or reduced autophagy. In cases with unstable pillars, LC3-II expression has been plant to be significantly reduced. after macrophage inflammasome hyperactivation, beget a rise in interleukin (IL)-1 stashing Complete loss of autophagy (as in ATG5-null cells) is inharmonious with life in humans and creatures, and according to some experts, a modest drop in autophagy isn't always related with experimental atherosclerosis, thus more severe dysfunctions in this system are anticipated. One of these could be gradational lysosomal impairment accompanied by an increase in p62, a protein that transports polyubiquitinated proteins to the autophagosome for lysosome-dependent degradation.

2. Ischemic Heart Disease

Atherossteosis (AS) is a common sexually transmitted disease common in developed countries. Because strengthening the accumulation within the arterial lumen, lipid cluster trading, increased vascular smooth muscle cell (VSMC), matrix development, calculation, and inflammation cause significant congestion. Color-based methods, such as electron microscopy, luminescence microscopy, and western methods, have been used to test autophagy in atherosclerotic stem cells (VSMCs, endothelial cells, macrophages) ten times. Based on the identification of autophagic p62 and LC3-II labels in stem cells, studies of dying samples and AS-rat models showed interactions or weight loss. In the case of unstable columns, the expression LC3-II has been inserted to significantly reduce it. After macrophage inflammasome hyperactivation, it produces an increase in interleukin (IL) -1 stashing. vascular strength in the test, so very poor performance in this system is expected. One of these could be lysosomal mice in the Gradational lysosomal overexpressing dominative-negative AMPK to show a reduced presentation of autophagy following ischemia. During recurrence, when physiological conditions are restored, AMPK is no longer active; therefore, based on previous findings, autophagy will likely continue to use the AMPK-independent medium, and some data suggest it occur with Beclin1 overexpression statistically, autophagy and mitophagy may be included as precautionary measures, but this may not make sense. Under conditions where the heart experiences energy loss, such as ischemia, the autophagic pathway may be protected, as it maintains rudimentary metabolic conditions; however, inclusion of autophagy under certain conditions, such as a period of recurrence, may be dangerous. In line with this hypothesis, Beclin1 inhibition has been reported to involve myocyte death *in vivo* further confirmation has emerged from the use of urocortin, a chronic cardiac peptide shown to reduce certain types of myocyte cell death. R; Urocortin lowers Beclin1 expression by phosphoinositide 3 (PI3) kinase / Akt Cardiac resuscitation is well tolerated to lead to PTPC use, the link between PTPC and autophagy (or mitophagy) function is unclear, and literature they are always arguing. As PTPC activation leads to apparent loss of mitochondrial membrane and mitochondria depolarization, the mitophagic method is expected to work. Indeed, the effectiveness of the mitophagic method is due to the action of PTPC in mice and hepatocyte mice and human liver while PTPC activation plays a role in confirming mitochhagy in the plant to aid both mitochondrial and calophagain 10 overexpression Also, PINK1 overdose. Stress on heart cells protects cells from death by significantly delaying the onset of PTPC when PINK1 is depleted, as in KO, the heart. SSBecomes a reduced risk in ex vivo IRI. Between PTPC exertion and autophagy / mitophagy, the response circle may remain where each path, too, controls the other bone. Exposure to PTPC may create an autophagic-dependent cell type in which multiple mitochondria are involved within a limited personality, but this process may cause embarrassment under greater damage where cells normally occur. On the other hand, a study led by Gustafsson AB suggested that BNIP3-dependent mitophagy (confirmed by hypoxia and heart failure in adult cardiomyocytes did not depend on PTPC function but required BNIP3 only and was

shown in conjunction with Becopy1 and autl). 5 Related (ATG5) Also, ER stress and non-reactive protein response (UPR) are linked to autophagy and mitophagy studies performed in both newborn and adult myocyte ventricular mice showed functional -ER stress and processes of UPR under I / R conditions. Indeed, hypoxia opens up the UPR to myocyte survival in infarcted boundary areas. -transge predisposed.cic murine modeI / R is reported to cause excessive mitochondrial rupture; the process can lead to the generation of two mitochondrial people through the rise or fall of the membrane. In most cases, a reduced number of people are not eligible to meet and go into mitophagy-based waste. Thus, mitophagy is dependent on mitochondrial rupture; Inhibition of a flexible process by exposure to the negative inhibitor of Drp1K38A or Fis1 RNA results in mutophagy mutations and subsequent accumulation of mitochondria-related mitochondria (MAMs), suppressing the regenerative sites of these mitochondria. proteins and attachments and the full fibers of that process Remote verification found in form 2 (INF2), ER-localized protein downstream Drp1, actin hair control and calcium exchange in MAMs from ER to ER mitochondria, which are important to confirm mitochondrial fission Further confirmation of mitophagy areas of the heart are described; similarly, the Fun14 sphere-containing protein 1 (FUNDC1), the LC3-associated mitophagy receptor, is responsible for the response. in hypoxia and is implicated in controlling mitochondrial homeostasis, monitoring heart rate in IRI, in mice models Indeed, loss of FUNDC1 activity by casein kinase 2α (CK2α) - intermediate phosphorylation leads to mitophagy inhibition and development Significant Towel Injury When *In vivo* infarction acute myocardial (MI) confirms permanent left artery in the development of mice, autophagy is developed to maintain ATP cellular levels and to cover cardio myocytes in the death of ischemic Protein group -mobility group- 1 (HMGB1) must be reset. in mitochondria and binds to mitophagy-related proteins after external administration. *In vivo* confirmation has shown that HMGB1 treatment in the murine model of acute MI may result in cardio myocyte survival, cardiovascular monitoring Apoptosis improves AMPK validation and inhibition of M TOR complex 1 (mTORC1) in mice I Mental hypertension HMGB1 has been shown to be a protein that promotes angiogenesis, restores heart function, and improves survival after myocardial infarction (MI).

3. Cardiomyopathies

- Cardiomyopathy (CM) is a cardiovascular disease characterized by abnormal myocardial infarction and function that occurs in the absence of other cardiovascular diseases (CVDs) such as coronary artery disease (CAD), uncontrolled high blood pressure (HT), and severe coronary heart disease. or the sever. heart failure. The term cardiomyopathy refers to a group of heart diseases. These diseases can affect people of all ages and races, and can have a variety of causes, symptoms, and treatments. Normal heart muscle may be thick, stiff, narrow, or full of foreign objects when cardiomyopathy strikes. As a result, the ability to pump heart muscle is affected, which can lead to abnormal heartbeat, pulmonary blood clots, and other problems. However, the exact pathophysiological processes are unknown. According to the National Heart, Lung, and Blood Institute, it is a common cause of sudden cardiac arrest in teens. Medications, exercise modifications, and surgery are all treatment options. Early detection and intervention can often help young people to get better results. Diabetic hearts show low glucose oxidation and high levels of FAO, leading to oxidative stress, reduced OXPHOS, and ultimately mitochondrial failure. Increased FAO potency does not save energy and mediates an increase in peroxisome proliferator-activated receptor (PPAR) activation. Additionally, Cardiomyocyte development and storage of Drp1, the small GTPase involved in mitochondrial fission in OMM, play a role in cardiac function and response to energy stress. Removal of Drp1 from cardiomyocytes results in decreased mitophagy and cardiac dysfunction, which increases the risk of IRI. According to Cahill TJ *et al*., A single modification of C452F in Drp1 creates a monogenic dilated CM and a series of mitochondrial abnormalities, including defective mitophagy. This conversion of missense into, Modification of Drp1 C452F results in monogenic dilated CM and a variety of mitochondrial diseases, including defective mitophagy. This missense modification has been identified as a promoter of Drp1 GTPase activity that prevents proteins from degrading after oligomerization, resulting in protein dysfunction. Python heart can be a powerful failure. Extended across the pathophysiology of DCM. On the other hand, the expression of insulin seems to have a second function: to prevent autophagy when a baby begins breastfeeding. Excess organic removal is caused by genetic removal of the insulin receptor, which adds to the loss of myocyte and HF. Overall, our data support the view that autophagy and mitophagy play a role in maintaining a healthy mitochondrial network and providing cardiovascular protection. Swelling of the legs, ankles and feet
- Bloating of the abdomen due to fluid buildup
- Cough while lying down
- Difficulty lying flat to sleep
- Fatigue
- Heartbeats that feel rapid, pounding or fluttering
- Chest discomfort or pressure
- Dizziness, lightheadedness and fainting

Restrictive cardiomyopathy

Restrictive cardiomyopathy (RCM) is a condition in which the heart chambers become harder over time. Despite its ability to squeeze, the heart cannot always rest between beats. This makes pumping blood very difficult for

the heart. Blood vessels close. Many of these symptoms are caused by fluid retention in the body, especially in the lungs. It also increases the pressure inside the ventricles, which may cause atrial fibrillation. An increased risk of developing abnormal heartbeat is also present. The heart is slowly losing its ability to pump as much blood as it could before. Most people with RCM have heart problems.

Mechanism of Restrictive cardiomyopathy

The stiff walls of the heart chambers (atria and ventricles) prevent them from filling completely, lowering preload and end-diastolic volume. As a result, blood flow is reduced, and blood volume that would normally enter the heart is backed up in the circulatory system. Diastolic dysfunction and heart failure develop in patients with limited cardiomyopathy over time. The most common causes are amyloidosis and heart scarring of unknown origin. It can also occur after a heart transplant. The chambers of the heart harden over time. The heart can contract well but not relax, resulting in a back-up in the circulatory system

Conclusion

In this review, we have provided a summary of the latest developments in our knowledge on chronic or medically controlled production of NO, H2S and CO in cardio protection from hypoxia and has been implicated in controlling mitochondrial homeostasis, heart monitoring at IRI, in the mouse model. Indeed, loss of FUNDC1 function by casein kinase 2α (CK2α) - intermediate phosphorylation leads to mitophagy inhibition and significant development of tissue damage During vivo acute myocardial infarction (MI) confirmed by chronic left ligation of the left coronary artery in transgenic mice, autophagy. is developed to maintain ATP cellular conditions and to cover cardio myocytes in ischemic death The ischemic protein High-mobility group-1 (HMGB1) is suitable for reconstitution in mitochondria and binds to mitophagy-related proteins after external administration. *In vivo* validation has shown that HMGB1 treatment in the murine MI model of acute MIcyte may result in cardio myocyte survival, cardiovascular monitoring Apoptosis is enabled to validate AMPK activation and inhibition of mTOR complex 1 (mTORC1) Trials in mice HMGB1 shows that protein enhances angiogenesis, restores heart function, and improves survival after myocardial infarction (MI) inhibition of autophagy in the heart, similar to that observed in macrophage-stimulating 1 (Mst1, proapoptotic kinase), associated with p62 concentration and complete correlation associated with autophagosomes exposure and cardiac dysfunction in mice below MI As presented earlier, a good balance between all mitochondrial quality control mechanisms is required for cell homeostasis. In IHD, a prominent component is played by mitochondrial biogenesis, the destruction of which is responsible for the altered energy output of the heart. 1α may be stimulated by a burst of long-term exercise training to restore the body, although the results may open new horizons in our view of the pathophysiology not only of myocardial ischemia-reperfusion, but in some cases within the circulatory system and beyond.

References

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med,2007:357:1121-1135.
2. Ibanez B, Heusch G, Ovize M, Van de, Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardio,2015:65:1454-1471.
3. Kleinbongard P, Amanakis G, Skyschally A, Heusch G. Reflection of cardioprotection by remote ischemic perconditioning in attenuated ST-segment elevation during ongoing coronary occlusion in pigs: evidence for cardioprotection from ischemic injury. Circ Res,2018:122:1102-1108
4. Hausenloy DJ, Botker HE, Engstrom T, Erlinge D, Heusch G, Ibanez B, *et al*. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J,2017:38:935-941.
5. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J,2017:38:774-784.
6. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, *et al*. Fourth universal definition of myocardial infarction, 2018. Eur Heart J 2018; doi: 10.1093/eurheartj/ehy462 [Epub ahead of print
7. Hausenloy DJ, Erik BH, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, *et al*. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res,2013:98:7-27.
8. Bulluck H, Yellon DM, Hausenloy DJ. Reducing myocardial infarct size: challenges and future opportunities. Heart,2016:102:341-348.
9. Hausenloy DJ, Garcia-Dorado D, Botker HE, Davidson SM, Downey J, Engel FB, *et al*. Novel targets and future strategies for acute cardioprotection: position paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res,2017:113:564-585.
10. Heusch G. Critical issues for the translation of cardioprotection. Circ Res,2017:120:1477-1486.
11. Heusch G. The coronary circulation as a target of cardioprotection. Circ Res,2016:118:1643-1658.
12. Partida RA, Libby P, Crea F, Jang IK. Plaque erosion: a new *in vivo* diagnosis and a potential major shift in the management of patients with acute coronary syndromes. Eur Heart J,2018:39:2070-2076.
13. Heusch G, Skyschally A, Kleinbongard P. Coronary microembolization and microvascular dysfunction. Int J Cardiol,2018:258:17-23.

14. Mills I, Fallon JT, Wrenn D, Sasken H, Gray W, Bier J, *et al.* Adaptive responses of coronary circulation and myocardium to chronic reduction in perfusion pressure and flow. Am J Physiol,1994:266:H447-H457.
15. Sorop O, Merkus D, de Beer VJ, Houweling B, Pistea A, McFalls EO, *et al.* Functional and structural adaptations of coronary microvessels distal to a chronic coronary artery stenosis. Circ Res,2008:102:795-803.
16. Dorge H, Neumann T, Behrends M, Skyschally A, Schulz R, Kasper C, *et al.* Perfusion-contraction mismatch with coronary microvascular obstruction: role of inflammation. Am J Physiol Heart Circ Physiol,2000:279:H2587-H2592.
17. Thielmann M, DöRge H, Martin C, Belosjorow S, Schwanke U, van de Sand A, *et al.* Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res,2002:90:807-813.
18. Herrmann J, Haude M, Lerman A, Schulz R, Volbracht L, Ge J *et al*. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. Circulation,2001:103:2339-2345.
19. Leineweber K, Bose D, Vogelsang M, Haude M, Erbel R, Heusch G. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J Am Coll Cardiol,2006:47:981-986.
20. Kleinbongard P, Bose D, Baars T, Mohlenkamp S, Konorza T, Schoner S, *et al*. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res,2011:108:344-352.
21. Skyschally A, Schulz R, Erbel R, Heusch G. Reduced coronary and inotropic reserves with coronary microembolization. Am J Physiol Heart Circ Physiol,2002:282:H611-H614.
22. Stempien-Otero A, Karsan A, Cornejo CJ, Xiang H, Eunson T, Morrison RS, *et al*. Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. J Biol Chem,1999:274:8039-8045.
23. Maxwell L, Gavin JB. The role of post-ischaemic reperfusion in the development of microvascular incompetence and ultrastructural damage in the myocardium. Basic Res Cardiol,1991:86:544-553.
24. Kasseckert SA, Schafer C, Kluger A, Gligorievski D, Tillmann J, Schluter KD, *et al*. Stimulation of cGMP signalling protects coronary endothelium against reperfusion-induced intercellular gap formation. Cardiovasc Res,2009:83:381-387.
25. Scotland RS, Cohen M, Foster P, Lovell M, Mathur A, Ahluwalia A, *et al*. C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci USA,2005:102:14452-14457. [PMC free article]
26. Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, *et al*. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest,2004:113:885-894. [PMC free article]
27. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol,2004:167:223-229. [PMC free article]
28. Betgem RP, de Waard GA, Nijveldt R, Beek AM, Escaned J, van RN. Intramyocardial haemorrhage after acute myocardial infarction. Nat Rev Cardiol,2015:12:156-167.
29. Liu Y, Lian K, Zhang L, Wang R, Yi F, Gao C, *et al*. TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. Basic Res Cardiol,2014:109:415.
30. Galaup A, Gomez E, Souktani R, Durand M, Cazes A, Monnot C, *et al*. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation,2012:125:140-149.
31. Mollenhauer M, Friedrichs K, Lange M, Gesenberg J, Remane L, Kerkenpaß C, *et al*. Myeloperoxidase mediates postischemic arrhythmogenic ventricular remodeling. Circ Res,2017:121:56-70. [PMC free article]
32. Bitencourt CS, Bessi VL, Huynh DN, Menard L, Lefebvre JS, Levesque T, *et al*. Cooperative role of endogenous leucotrienes and platelet-activating factor in ischaemia-reperfusion-mediated tissue injury. J Cell Mol Med,2013:17:1554-1565.
33. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature,2005:437:497-504.
34. Feng Y, Venema VJ, Venema RC, Tsai N, Behzadian MA, Caldwell RB. VEGF-induced permeability increase is mediated by caveolae. Invest Ophthalmol Vis Sci,1999:40:157-167.
35. Lee SW, Won JY, Lee HY, Lee HJ, Youn SW, Lee JY, *et al*. Angiopoietin-1 protects heart against ischemia/reperfusion injury through VE-cadherin dephosphorylation and myocardiac integrin-β1/ERK/caspase-9 phosphorylation cascade. Mol Med,2011:17:1095-1106.
36. Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, *et al*. Capillary pericytes regulate cerebral blood flow in health and disease. Nature,2014:508:55-60.
37. Nees S, Weiss DR, Senftl A, Knott M, Forch S, Schnurr M, *et al.* Isolation, bulk cultivation, and characterization of coronary microvascular pericytes: the second most frequent myocardial cell type *in vitro*. Am J Physiol Heart Circ Physiol,2012:302:H69-H84.
38. O'Farrell FM, Mastitskaya S, Hammond-Haley M, Freitas F, Wah WR, Attwell D. Capillary pericytes mediate coronary no-reflow after myocardial ischaemia. Elife, 2017, 6. pii:e29280. doi:10.7554/eLife.29280.

39. Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol,2010:105:687-701.
40. van den Berg BM, Vink H, Spaan JA. The endothelial glycocalyx protects against myocardial edema. Circ Res,2003:92:592-594.
41. Chappell D, Dorfler N, Jacob M, Rehm M, Welsch U, Conzen P. Glycocalyx protection reduces leukocyte adhesion after ischemia/reperfusion. Shock,2010:34:133-139.
42. Chappell D, Brettner F, Doerfler N, Jacob M, Rehm M, Bruegger D, *et al*. Protection of glycocalyx decreases platelet adhesion after ischaemia/reperfusion: an animal study. Eur J Anaesthesiol,2014:31:474-481.
43. Chappell D, Hofmann-Kiefer K, Jacob M, Rehm M, Briegel J, Welsch U, *et al*. TNF-alpha induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin. Basic Res Cardiol,2009:104:78-89.
44. Bruegger D, Rehm M, Jacob M, Chappell D, Stoeckelhuber M, Welsch U, *et al*. Exogenous nitric oxide requires an endothelial glycocalyx to prevent postischemic coronary vascular leak in guinea pig hearts. Crit Care,2008:12:R73.